CD33 and acute myeloid leukemia: Indeed, a recent fatal event in a clinical trial of allogeneic CAR-T-cells targeting CD123 [9], severe pancytopenia in an AML patient treated with anti-CD33 CAR-T-cells [10], and impaired hematopoiesis in xenograft models of human hematopoiesis have been described [4,5].